365 related articles for article (PubMed ID: 34607452)
1. Neutralization of SARS-CoV-2 Variants of Concern Harboring Q677H.
Zeng C; Evans JP; Faraone JN; Qu P; Zheng YM; Saif L; Oltz EM; Lozanski G; Gumina RJ; Liu SL
mBio; 2021 Oct; 12(5):e0251021. PubMed ID: 34607452
[TBL] [Abstract][Full Text] [Related]
2. Emergence of Multiple SARS-CoV-2 Antibody Escape Variants in an Immunocompromised Host Undergoing Convalescent Plasma Treatment.
Chen L; Zody MC; Di Germanio C; Martinelli R; Mediavilla JR; Cunningham MH; Composto K; Chow KF; Kordalewska M; Corvelo A; Oschwald DM; Fennessey S; Zetkulic M; Dar S; Kramer Y; Mathema B; Germer S; Stone M; Simmons G; Busch MP; Maniatis T; Perlin DS; Kreiswirth BN
mSphere; 2021 Aug; 6(4):e0048021. PubMed ID: 34431691
[TBL] [Abstract][Full Text] [Related]
3. The Impact on Infectivity and Neutralization Efficiency of SARS-CoV-2 Lineage B.1.351 Pseudovirus.
Kim YJ; Jang US; Soh SM; Lee JY; Lee HR
Viruses; 2021 Apr; 13(4):. PubMed ID: 33917138
[TBL] [Abstract][Full Text] [Related]
4. Functional Analysis of Spike from SARS-CoV-2 Variants Reveals the Role of Distinct Mutations in Neutralization Potential and Viral Infectivity.
Kuzmina A; Wattad S; Engel S; Rosenberg E; Taube R
Viruses; 2022 Apr; 14(4):. PubMed ID: 35458533
[TBL] [Abstract][Full Text] [Related]
5. The Biological Functions and Clinical Significance of SARS-CoV-2 Variants of Corcern.
Akkız H
Front Med (Lausanne); 2022; 9():849217. PubMed ID: 35669924
[TBL] [Abstract][Full Text] [Related]
6. Epitope Classification and RBD Binding Properties of Neutralizing Antibodies Against SARS-CoV-2 Variants of Concern.
Deshpande A; Harris BD; Martinez-Sobrido L; Kobie JJ; Walter MR
Front Immunol; 2021; 12():691715. PubMed ID: 34149735
[TBL] [Abstract][Full Text] [Related]
7. Comprehensive mapping of binding hot spots of SARS-CoV-2 RBD-specific neutralizing antibodies for tracking immune escape variants.
Yi C; Sun X; Lin Y; Gu C; Ding L; Lu X; Yang Z; Zhang Y; Ma L; Gu W; Qu A; Zhou X; Li X; Xu J; Ling Z; Xie Y; Lu H; Sun B
Genome Med; 2021 Oct; 13(1):164. PubMed ID: 34649620
[TBL] [Abstract][Full Text] [Related]
8. The impact of spike N501Y mutation on neutralizing activity and RBD binding of SARS-CoV-2 convalescent serum.
Lu L; Chu AW; Zhang RR; Chan WM; Ip JD; Tsoi HW; Chen LL; Cai JP; Lung DC; Tam AR; Yau YS; Kwan MY; To WK; Tsang OT; Lee LL; Yi H; Ip TC; Poon RW; Siu GK; Mok BW; Cheng VC; Chan KH; Yuen KY; Hung IF; To KK
EBioMedicine; 2021 Sep; 71():103544. PubMed ID: 34419925
[TBL] [Abstract][Full Text] [Related]
9. Impact of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Variant-Associated Receptor Binding Domain (RBD) Mutations on the Susceptibility to Serum Antibodies Elicited by Coronavirus Disease 2019 (COVID-19) Infection or Vaccination.
Chen LL; Lu L; Choi CY; Cai JP; Tsoi HW; Chu AW; Ip JD; Chan WM; Zhang RR; Zhang X; Tam AR; Lau DP; To WK; Que TL; Yip CC; Chan KH; Cheng VC; Yuen KY; Hung IF; To KK
Clin Infect Dis; 2022 May; 74(9):1623-1630. PubMed ID: 34309648
[TBL] [Abstract][Full Text] [Related]
10. Antibody cocktail effective against variants of SARS-CoV-2.
Liang KH; Chiang PY; Ko SH; Chou YC; Lu RM; Lin HT; Chen WY; Lin YL; Tao MH; Jan JT; Wu HC
J Biomed Sci; 2021 Nov; 28(1):80. PubMed ID: 34814920
[TBL] [Abstract][Full Text] [Related]
11. RBD-mRNA vaccine induces broadly neutralizing antibodies against Omicron and multiple other variants and protects mice from SARS-CoV-2 challenge.
Shi J; Zheng J; Zhang X; Tai W; Odle AE; Perlman S; Du L
Transl Res; 2022 Oct; 248():11-21. PubMed ID: 35489692
[TBL] [Abstract][Full Text] [Related]
12. Antigenicity of the Mu (B.1.621) and A.2.5 SARS-CoV-2 Spikes.
Chatterjee D; Tauzin A; Laumaea A; Gong SY; Bo Y; Guilbault A; Goyette G; Bourassa C; Gendron-Lepage G; Medjahed H; Richard J; Moreira S; Côté M; Finzi A
Viruses; 2022 Jan; 14(1):. PubMed ID: 35062348
[TBL] [Abstract][Full Text] [Related]
13. Vaccine-escape and fast-growing mutations in the United Kingdom, the United States, Singapore, Spain, India, and other COVID-19-devastated countries.
Wang R; Chen J; Gao K; Wei GW
Genomics; 2021 Jul; 113(4):2158-2170. PubMed ID: 34004284
[TBL] [Abstract][Full Text] [Related]
14. Key Substitutions in the Spike Protein of SARS-CoV-2 Variants Can Predict Resistance to Monoclonal Antibodies, but Other Substitutions Can Modify the Effects.
Lusvarghi S; Wang W; Herrup R; Neerukonda SN; Vassell R; Bentley L; Eakin AE; Erlandson KJ; Weiss CD
J Virol; 2022 Jan; 96(1):e0111021. PubMed ID: 34668774
[TBL] [Abstract][Full Text] [Related]
15. Humoral immune response to circulating SARS-CoV-2 variants elicited by inactivated and RBD-subunit vaccines.
Cao Y; Yisimayi A; Bai Y; Huang W; Li X; Zhang Z; Yuan T; An R; Wang J; Xiao T; Du S; Ma W; Song L; Li Y; Li X; Song W; Wu J; Liu S; Li X; Zhang Y; Su B; Guo X; Wei Y; Gao C; Zhang N; Zhang Y; Dou Y; Xu X; Shi R; Lu B; Jin R; Ma Y; Qin C; Wang Y; Feng Y; Xiao J; Xie XS
Cell Res; 2021 Jul; 31(7):732-741. PubMed ID: 34021265
[TBL] [Abstract][Full Text] [Related]
16. Functional Antibodies Against SARS-CoV-2 Receptor Binding Domain Variants with Mutations N501Y or E484K in Human Milk from COVID-19-Vaccinated, -Recovered, and -Unvaccinated Women.
Demers-Mathieu V; Hakansson AP; Hall S; Lavangnananda S; Fels S; Medo E
Breastfeed Med; 2022 Feb; 17(2):163-172. PubMed ID: 34809492
[No Abstract] [Full Text] [Related]
17. The alpha/B.1.1.7 SARS-CoV-2 variant exhibits significantly higher affinity for ACE-2 and requires lower inoculation doses to cause disease in K18-hACE2 mice.
Bayarri-Olmos R; Johnsen LB; Idorn M; Reinert LS; Rosbjerg A; Vang S; Hansen CB; Helgstrand C; Bjelke JR; Bak-Thomsen T; Paludan SR; Garred P; Skjoedt MO
Elife; 2021 Nov; 10():. PubMed ID: 34821555
[TBL] [Abstract][Full Text] [Related]
18. Serum Neutralizing Activity of mRNA-1273 against SARS-CoV-2 Variants.
Choi A; Koch M; Wu K; Dixon G; Oestreicher J; Legault H; Stewart-Jones GBE; Colpitts T; Pajon R; Bennett H; Carfi A; Edwards DK
J Virol; 2021 Nov; 95(23):e0131321. PubMed ID: 34549975
[TBL] [Abstract][Full Text] [Related]
19. In vitro data suggest that Indian delta variant B.1.617 of SARS-CoV-2 escapes neutralization by both receptor affinity and immune evasion.
Augusto G; Mohsen MO; Zinkhan S; Liu X; Vogel M; Bachmann MF
Allergy; 2022 Jan; 77(1):111-117. PubMed ID: 34453338
[TBL] [Abstract][Full Text] [Related]
20. E484K and N501Y SARS-CoV 2 spike mutants Increase ACE2 recognition but reduce affinity for neutralizing antibody.
Chakraborty S
Int Immunopharmacol; 2022 Jan; 102():108424. PubMed ID: 34915409
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]